Share Price vs News Releases - poor correlationBack in April 2020, I posted that share price vs news releases was very iffy until it wasn't, sic.
I used Bellus, Trillium and Sernova as examples.
Bioteck's comment about hemophilia and lack of share price response is valid. That said, at some point the tide turns and news prompts a definite response in share price.
Further, Virtual Mesa will have eyes of Big Pharma discerning the proceedings. Ultimately, it will be Big Pharma rather than news that will drive Sernova's valuation.
Bioteck, for whatever reason that he's been unable to explain, has a permanently jaundiced view of Sernova. His outlook for what Sernova has (and not his focus on share price) would be more balanced if he were (subjunctive case) to be able to interpret the nuances in the releases better.
Below, I give my April posts for Trillium and for Sernova.
jwall n.b. Some of the links use the TMX website, which was subsequently completely remodelled. The two links below should be used for Sernova's and Trillium's news releases should the reader wish to check. https://www.baystreet.ca/quotedata/TRIL-CA/fullnewssummary/
https://www.baystreet.ca/quotedata/SVA-CA/fullnewssummary/ Trillium: TRIL was trading in the high 30 to low 40 cent area for quite some time in 2019. A TRIL on the charts; choose six months
On Decembers 11, 19 and 31 of 2019 we got the start of share price breaks upwards for no apparent reason. (There was no news.) 
Major news came out 7 January, 2020. This kick-started the share price upwards 8 Jan 2020. 
January 22 and February 27, 2020 saw the start of two more major legs up, but there was no news. A TRIL a minute's news releases
Trillium is one illustration where news seemed not to make an impact on the share price save 7 Jan 2020. Nothing was happening in the thirty and forty cent areas until something did happen. 
My conjecture is something similar (nothing and then something) is possible for Sernova (SVA - TSXV). 
jwall 
Sernova: Sernova (SVA - TSXV) $$ progression... completes the analogy with BLU & TRIL
SVA has had a very choppy closing price trading history, see five year chart. SVA has meandered from low teens (present price) to as high as almost 50 cents for a closing price over the last five years. Intrepid shareholders know Sernova is all about The Pouch (to treat numerous human complaints), "factors" (e.g. hemophilia) and stem type cells for various applications! 
Going back to 2015, we get no apparent correlation between news and share price save some of the peaks happened when news was released followed by a drop in price.... This is similar to what we keep seeing "today". 
This lack of correlation with news continued into 2016. In late May 2016, the share price spiked on no news, but a PP that closed end of June saw a sharp dip at that time. 
News, 12 July, 2016, on money from JDRF to fund the FDA trial for Type I diabetes coincided with a price spike and subsequent price drop. This decline continued as a slow erosion to mid-October 2017 regardless of any news.
We then got a major leg up on no news until, 11 Dec 2017, with news of FDA approval to start the trial. This resulted in a peak, fallback and then continued uptrend to a peak of 49.5 cent, 4 Jan 2018.
The share price then slowly eroded with an intermediate spike at 44 cents, 22 Feb 2018, on news Medtronic's instrumentation would be used in the FDA trial. 
The share price continued to decline until a spike to 37 cents, 14 May 2018, on news U of Chicago approved the go ahead for the trial.
The share price then started to drop quickly. The reason turned out to be a PP at $0.25 that closed 23 July 2018. The share price continued to fall regardless of news of any kind until a close of 15 cents, 26 March 2019. 
The share price started to rally and peaked at 26 cents, 3 July, 2019, on scientifically worded news that The Pouch was working AOK. The share price then declined to a close of 17 cents, 1 August, 2019. A PP was announced in late July 2019. 
The share price started to rally and climbed to a close of 28 cents, 2 October, 2019 (about the time ViaCyte announced news on C-Peptides). Sernova responded 16 October, 2019, but the share price rallied slightly only to close at 25 cents.
There was a small rally (no news) to close at 21 cents, 4 Dec, 2019. The share price declined to 6 Feb, 2020 and then rallied to peaks of 20 cents, 12 - 14 Feb, 2020, on good news, 13 Feb, 2020, on the long overdue status of the Sentinel pouch.
Since then, COVID-19 has been hurting the markets badly and everything has fallen out of bed in sympathy. The excellent technical news, 24 March, 2020, resulted in a muted rally to 12.5 cents and a close of 11.5 cents.
The above share price vs news timeline clearly shows shareholders and interested parties in Sernova want FDA trial news badly. Further, it appears that news may need a better story flow in addition to the scientific slant to be better received by the market. To be sure pharmaceutical companies understand the science, but shareholders need "the vernacular" to get the significance. 
My conjecture (like for both TRIL and BLU) is nothing and then something for Sernova's share price (SVA - TSXV). A major share price move now requires either a significant collaboration, or a complete Buy, Bye. 
jwall